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b-Blockers are known to improve postoperative outcome
after major vascular surgery. We studied the effects of
b-blockers in 2126 vascular surgery patients with and without
kidney disease followed for 14 years. Creatinine clearance
was calculated using the Cockcroft–Gault equation, and
kidney function was categorized as Stage 1 for a reference
group of 550 patients, Stage 2 with 808 patients, Stage 3 with
627 patients, and combined Stages 4 and 5 with 141 patients.
Outcome measures were 30-day and long-term all-cause
mortality with a mean follow-up of 6 years. Cox proportional
hazards models were used to control cardiovascular risk
factors, including propensity for b-blocker use. In all, 129 (6%)
and 1190 (56%) patients died respectively. Mortality rates
were three- and two-fold higher, respectively, for patients at
Stages 3–5 compared to the reference group for the two
outcomes. b-Blocker use was significantly associated with a
lower risk of mortality after surgery. The overall adjusted
hazard ratio was 0.35 and 0.62, respectively, for individuals at
Stages 3–5 compared to the reference group for 30-day and
long-term mortality. This study shows that kidney function is
a predictor of all-cause mortality and b-blocker use is
associated with a lower risk of death in kidney disease
patients undergoing elective vascular surgery.
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Recent estimates suggest that more than 20 million people
have chronic kidney disease (CKD) in the US alone.1
Furthermore, the CKD and dialysis populations are growing
rapidly and are expected to exceed 30 million and 650 000,
respectively, in the US by 2010.2 In fact, progression of CKD
exposes patients to an increased risk of development of
vascular disease and cardiovascular morbidity and mortal-
ity.3,4 In addition, it has recently been established that
individuals with CKD are at moderately increased risk for
developing abdominal aortic aneurysm (AAA) and peri-
pheral arterial disease.5,6
Perioperative and long-term outcomes after vascular
surgery are mainly dependent on the presence and extent
of traditional cardiovascular risk factors, including hyper-
tension, diabetes, dyslipidemia, and smoking, which are
commonly present in patients with CKD.7–10 Numerous
studies have shown that CKD may be associated with higher
rates of morbidity and mortality when these patients undergo
open infrarenal AAA repair.11,12 In addition, even moderate
CKD seems to be a risk factor for postoperative death
and complications after lower extremity revascularization
procedures.13
To improve perioperative myocardial ischemia and long-
term cardiovascular complications after noncardiac surgery,
guidelines recommend b-blocker therapy in all patients at
high risk for coronary artery disease.14,15 Given the proven
benefit of b-blockers in patients with normal kidney function
with cardiac co-morbidities, b-blockers would seem to be
attractive agents to reduce cardiovascular morbidity and
mortality associated with noncardiac surgery in the CKD
population. Hence, the purpose of this observational study
was to describe the association of b-blocker therapy on short-
and long-term outcomes of patients undergoing major
noncardiac vascular surgery, for different stages of kidney
dysfunction.
RESULTS
Patient characteristics
The mean age of all 2126 patients was 66711 years, 76%
were male and half of patients underwent AAA surgery
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(51%). The mean follow-up was 5.9873.68 years (median,
6.21 years).
A total of 757 (36%) patients received b-blockers before
surgery. b-Blocker users had a higher prevalence of
cardiovascular risk factors (hypertension, chronic obstructive
pulmonary disease (COPD), diabetes mellitus, hypercholes-
terolemia, and current history of smoking; Po0.001 for all),
a higher proportion of patients with a history of cardiovas-
cular disease (myocardial infarction (MI), coronary revascu-
larization, heart failure, angina, and cerebrovascular disease;
Po0.01 for all), and additional medication use (including
statins, angiotensin-converting enzyme inhibitors (ACE)
inhibitors, anti-coagulants, and calcium antagonists;
Po0.001 for all). Importantly, no difference in baseline
kidney function, assessed by serum creatinine or creatinine
clearance (CrCl), was observed (P¼ 0.3 and 0.9, respec-
tively). Of note, patients using b-blockers underwent more
AAA surgeries and less limb arterial revascularization
procedures (Po0.001 for all).
The mean serum creatinine concentration and CrCl in this
population was 1.2771.1 mg dl1 and 74.0734 ml min1,
respectively, and 768 (36%) patients had a CrCl
o60 ml min1 (mean CrCl 42.7714 ml min1; Table 1). A
total of 550 (26%) patients had a CrCl of X90 ml min1;
38% (n¼ 808) had a CrCl of 60–89 ml min1; 30% (n¼ 627)
had a CrCl of 30–59 ml min1; and 7% (141) had a CrCl of
o30 ml min1.
Patients with lower CrCl levels had significantly higher
proportions of hypertension, hypercholesterolemia, COPD,
history of MI, heart failure, angina, and cerebrovascular
disease and they received more diuretics, ACE inhibitors,
calcium antagonists, and nitrates. Importantly, no difference
in b-blocker use was found between the different kidney
function groups (P¼ 0.1).
Of the subjects with a CrClo60 ml min1, 268 (35%)
patients were receiving b-blockers. Baseline characteristics are
summarized in Table 2. Patients with a CrClo60 ml min1
and receiving b-blockers were younger, had a higher
proportion of traditional cardiovascular risk factors—includ-
ing a history of hypertension, diabetes, and elevated
cholesterol level—higher prevalence of cardiovascular dis-
ease, and usage of other cardioprotective medications
including ACE inhibitors and statins. No differences were
observed in the mean serum creatinine and CrCl.
Propensity score analysis
Within the propensity score analysis, the following baseline
variables significantly predicted b-blocker therapy: hyperten-
sion (odds ratio (OR) 1.48, 95% confidence interval (CI):
1.16–1.88), history of MI (OR 1.78, 95% CI: 1.39–2.27),
coronary revascularization (OR 1.65, 95% CI: 1.30–2.10),
AAA surgery (OR 1.84, 95% CI: 1.49–2.29), and year of
operation per 2 years of increase (OR 1.25, 95% CI:
1.61–1.34). According to medical therapy, usage of statins
(OR 2.06, 95% CI: 1.56–2.72), diuretics (OR 1.39, 95% CI:
1.07–1.82), calcium antagonist (OR 1.78, 95% CI: 1.41–2.25),
nitrates (OR 2.61, 95% CI: 2.00–3.41), and ACE inhibitors
(OR 1.27, 95% CI: 1.01–1.62) were significant predictors of
b-blocker prescription. The graphical method of examination
by box plots showed a balance of the estimated propensity
score between b-blocker users and b-blocker non-users
within each decile of the propensity score.
Short-term outcome
In total, 129 (6.1%) patients died within 30 days after
surgery. A clear relationship between the levels of kidney
function and short-term mortality was observed. For patients
with a baseline CrClX90, 60–89, 30–59, and o30 ml min1,
the mortality within 30 days was 2.7, 4.5, 9.3, and 14.2%,
respectively (P¼o0.001; Table 3). Patients with mild
impairment of kidney function, that is CrCl 60–89 ml min1,
were not associated with adverse short-term outcome (OR
1.21, 95% CI: 0.62–2.36) when compared with the reference
group. When CrCl was evaluated as a continuous variable,
the adjusted OR for short-term mortality was 1.02 (95% CI:
1.01–1.04) per 1 ml min1 decrease in CrCl (Po0.001). In
addition, b-blocker therapy was associated with improved
short-term outcome for the whole cohort (adjusted OR 0.39,
95% CI: 0.24–0.64). In addition, b-blocker use was associated
with a lesser risk of all-cause mortality for patients with a
CrClX60 ml min1 (adjusted OR 0.39, 95% CI: 0.19–0.83)
and for patients with a CrClo60 ml min1 (adjusted OR
0.35, 95% CI: 0.19–0.72; Table 4).
Long-term outcome
During 5.9873.68 years of follow-up, 1190 (56%) patients
died. All-cause mortality rates according to baseline kidney
function were 36.2, 53.7, 70.2, and 83.0% for patients with a
baseline CrClX90, 60–89, 30–59, and o30 ml min1, respec-
tively (Po0.001; Figure 1). Importantly, even patients with
mild kidney dysfunction, that is CrCl 60–89 ml min1, were
at significant higher risk (adjusted hazard ratio (HR) 1.20,
95% CI: 1.01–1.44; Table 3), compared to patients with
normal kidney function. When CrCl was evaluated as a
continuous variable, the adjusted HR for long-term mortality
was 1.01 (95% CI: 1.01–1.02) per 1 ml min1 decrease in CrCl
(Po0.001). During this observation period, b-blocker use
remained an independent predictor for long-term survival in
all patients (adjusted HR 0.82, 95% CI: 0.71–0.93; Table 4).
As shown in Figure 2, the association of b-blocker therapy
was more pronounced in patients with a baseline CrCl of
o60 ml min1 (adjusted HR 0.62, 95% CI: 0.50–0.76),
compared to patients with a CrCl ofX60 ml min1 (adjusted
HR 1.01, 95% CI: 0.84–1.22).
DISCUSSION
In this cohort of men and women who underwent elective
vascular surgery, the level of kidney function is an
independent predictor of short- and long-term mortality.
We also found that the risk of all-cause mortality increased
progressively with decreasing kidney function. In particular,
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patients with a CrClo60 ml min1 were more likely to have a
significant risk of death in the first 30 days or in the first 10
years after surgery when compared with patients without
kidney impairment after controlling for demographic and
clinical variables. In addition, perioperative b-blocker use
was associated with a 65 and 38% reduction in the short-
and long-term all-cause mortality in patients with a
CrClo60 ml min1, respectively. To our knowledge, there
are a few observational studies of the relationship between
kidney dysfunction, noncardiac surgery outcomes, and
b-blocker use.
Cardiovascular disease is the major cause of morbidity and
mortality in the Western world.16 Acute and long-term
therapy with b-blockers has become a standard of care of
patients with acute myocardial infarction and congestive
heart failure.17 In nonrenal patients, b-blocker therapy has
been shown to reduce infarct size and mortality among MI
patients.16 In addition, in a recent meta-analysis, b-blockers
were shown to have a large beneficial effect on hospitaliza-
tions and all-cause mortality in stable patients with New York
Heart Association class II or III heart failure and normal
kidney function.18 The main proposed mechanisms under-
lying the efficacy of b-blockers include decreasing cardiac
energy requirements and modification of arrhythmias risk by
antagonizing the deleterious effects of the sympathetic
nervous system.19
Although the increased risk of cardiovascular events
among persons with kidney disease not requiring dialysis is
well established, the mechanism explaining the increased risk
of cardiovascular death in patients with kidney dysfunction is
the focus of the ongoing investigation.20 Multiple possible
explanations have been proposed to explain the association
between kidney dysfunction and increased risks of death
and cardiovascular disease, including left ventricular hyper-
trophy,21 endothelial dysfunction,22 arterial stiffness,23 and
increased levels of inflammatory factors.24
In addition to the above factors, sympathetic nervous
system activation likely plays a significant role in the
increased cardiovascular risk of patients with kidney disease.
Increased sympathetic activity is now recognized as an
important mechanism involved in cardiovascular complica-
tions in subjects with end-stage renal disease.25,26 A recent
review by Bakris et al.27 assessed an abundance of experi-
mental and human data linking kidney disease to the
activation of the sympathetic nervous system. Using different
models of kidney injury, such as renal artery ligation and 5/6
nephrectomy, it has been shown that kidney damage is
associated with increased afferent sympathetic activity.28–30
Table 1 | Baseline characteristics of all patients, according to the level of baseline kidney function
All patients X90 ml min1 60–89 ml min1 30–59 ml min1 o30 ml min1
N=2126 (100%) N=550 (26%) N=808 (38%) N=627 (30%) N=141 (7%) P-value
Demographics
Mean age (7s.d.) 66.4 (711) 56.9 (711) 67.6 (79) 72.7 (78) 67.8 (713) o0.001
Male (%) 76 79 78 73 63 o0.001
Abdominal aorta surgery 51 46 54 54 45 0.003
Lower limb arterial revascularization surgery 49 55 46 46 55 0.003
Cardiovascular risk factor (%)
Hypertension 49 41 50 51 64 o0.001
Diabetes mellitus 16 15 16 17 21 0.5
Current smoker 27 27 30 26 24 0.3
Hypercholesterolemia 20 22 23 14 16 o0.001
COPD 21 18 24 23 15 0.008
Body mass index (7s.d.) 24.8 (75) 26.2 (74) 24.7 (74) 24.1 (76) 22.2 (74) o0.001
Serum creatinine (7s.d.) 1.27 (71.1) 0.79 (70.2) 0.99 (70.2) 1.3 (70.4) 3.61 (72.8) o0.001
Creatinine clearance (7s.d.) 74.0 (734) 117.6 (728) 74.0 (78) 48 (78) 18.3 (78) o0.001
Disease history (%)
Myocardial infarction 29 21 30 33 36 o0.001
Coronary revascularization 26 25 28 26 22 0.5
Heart failure 7 4 6 8 14 o0.001
Angina 17 13 18 20 16 0.01
Cerebrovascular disease 7 4 7 9 15 o0.001
Medication use (%)
b-Blockers 36 33 38 34 40 0.1
Statins 26 29 29 21 19 o0.001
Diuretics 20 13 19 27 31 o0.001
ACE inhibitors 34 27 34 38 45 o0.001
Calcium antagonists 36 29 37 37 51 o0.001
Nitrates 20 16 19 23 31 o0.001
Aspirin 32 31 32 33 29 0.7
Anti-coagulation 24 26 25 22 19 0.2
ACE inhibitors, angiotensin-converting enzyme inhibitors; COPD, chronic obstructive pulmonary disease; s.d., standard deviation.
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Furthermore, Klein et al.31 recently reported that sympathetic
activity was inappropriately high in a group of 57 patients
with renal parenchymal disease. The authors hypothesized
that renal structural changes lead to stimulation of the
sympathetic nervous system by causing local or diffuse renal
ischemia, which has been reported to stimulate renal afferents
in animal experiments. In addition to renal afferent
sympathetic discharge, there are other plausible mechanisms
connecting kidney disease to sympathetic overactivity,32
including elevated angiotensin II,33 and suppressed brain
nitric oxide. Hence, the factors responsible for sympathetic
activation in patients with CKD appear to be multifactorial.
Table 2 | Baseline characteristics of patients with a creatinine clearance o60 ml min1, according to b-blocker use
All patients b-Blocker use No b-blocker use
N=768 (100%) N=268 (35%) N=500 (65%) P-value
Demographics
Mean age (7s.d.) 71.7 (79) 70.7 (78) 72.4 (710) 0.02
Male (%) 71 70 72 0.6
Abdominal aortic surgery 52 59 49 o0.001
Lower limb arterial revascularization surgery 48 41 51 o0.001
Cardiovascular risk factor (%)
Hypertension 53 71 43 o0.001
Diabetes mellitus 17 21 15 0.041
Current smoker 26 29 24 0.1
Hypercholesterolemia 15 22 11 o0.001
COPD 21 24 19 0.1
Body mass index (7s.d.) 23.7 (76) 23.5 (74) 23.9 (77) 0.5
Disease history (%)
Myocardial infarction 33 46 27 o0.001
Coronary revascularization 25 35 20 o0.001
Heart failure 9 12 8 0.1
Angina 19 28 14 o0.001
Cerebrovascular disease 10 16 7 o0.001
Medication use (%)
Statins 20 35 13 o0.001
Diuretics 27 36 23 o0.001
ACE inhibitors 39 52 32 o0.001
Calcium antagonists 40 58 29 o0.001
Nitrates 24 36 18 o0.001
Aspirin 32 41 28 o0.001
Anti-coagulation 22 25 20 0.06
Baseline kidney function (%)
Serum creatinine (7s.d.) 1.90 (71.7) 1.99 (71.8) 1.85 (71.7) 0.3
Creatinine clearance (7s.d.) 42.7 (714) 42.3 (715) 42.9 (714) 0.6
ACE inhibitors, angiotensin-converting enzyme inhibitors; COPD, chronic obstructive pulmonary disease; s.d., standard deviation.
Table 3 | Multivariate associations of the level of baseline kidney function and short- and long-term mortality
Short-term all-cause mortality Long-term all-cause mortality
Unadjusted
Adjusted for
confoundersa
Adjusted for
confounders and
propensity scoreb Unadjusted
Adjusted for
confoundersa
Adjusted for
confounders and
propensity scoreb
OR (95% CI) OR (95% CI) OR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
All patients (n=2126)
CrCl X90 ml min1 (ref.) 1.0 1.0 1.0 1.0 1.0 1.0
CrCl 60–89 ml min1 1.66 (0.90–3.07) 1.16 (0.60–2.24) 1.21 (0.62–2.36) 1.68 (1.42–1.99) 1.19 (1.02–1.43) 1.20 (1.01–1.44)
CrCl 30–59 ml min1 3.64 (2.04–6.50) 2.29 (1.16–4.53) 2.30 (1.16–4.54) 2.64 (2.23–3.12) 1.64 (1.35–2.00) 1.63 (1.33–1.97)
CrClo30 ml min1 5.90 (2.93–11.85) 4.96 (2.27–10.83) 5.32 (2.42–11.69) 5.32 (4.23–6.70) 3.89 (3.02–5.01) 4.00 (3.10–5.16)
ACE inhibitors, angiotensin-converting enzyme inhibitors; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CrCl, creatinine clearance; HR, hazard ratio;
OR, odds ratio.
aAdjusted for age, gender, hypertension, diabetes mellitus, smoking, hypercholesterolemia, COPD, body mass index, type of surgery, history of myocardial infarction, coronary
revascularization, heart failure, angina, cerebrovascular disease, and year of operation.
bAdjusted for age, gender, hypertension, diabetes mellitus, smoking, hypercholesterolemia, COPD, body mass index, type of surgery, history of myocardial infarction, coronary
revascularization, heart failure, angina, cerebrovascular disease, year of operation, statins, diuretics, ACE inhibitors, calcium antagonists, nitrates, aspirin, and anti-coagulations.
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The sympathetic nervous system, by acting through b1 and
b2 receptors, in addition to its effect on myocardial
repolarization, can increase heart rate, which not only
adversely affects the relation between myocardial demand
and supply, but can also alter the structure and function of
the heart, in particular by causing hypertrophy and fibrosis.19
Therefore, the use of adrenergic inhibitors is a logical strategy
to examine whether interference with the sympathetic system
reduces the high cardiovascular morbidity and mortality of
patients with kidney dysfunction. Although several observa-
tional studies and a small randomized trial34–36 suggest
definite survival benefits derived from the use of b-blockers
in hemodialysis patients, there are a few data on the use of b-
blockers in treating patients with different stages of kidney
dysfunction and its relationship with short- and long-term
outcomes after major noncardiac surgery. Of note, b-blockers
have been associated with a reduction in mortality in 419
patients with renal insufficiency and heart failure in a
Canadian prospective study.37
Estimates of b-blocker use in patients with kidney disease
vary, but all studies show that b-blockers are used by only a
minority of patients. The US Renal Data System Waves 3 and
4 studies observe that only 8.5% of the chronic dialysis
patient population was using a b-blocker.34 In addition,
available data indicate that the actual use of b-blockers in
patients with kidney dysfunction actually decreases as the
kidney function declines.38 McAlister et al.37 and Gibney
et al.39 have reported that only 18 and 32% of CKD patients
with heart failure and post-coronary artery bypass graft were
receiving b-blockers, respectively. These observations are
consistent with our findings as only 35% of patients of our
cohort with a CrClo60 ml min1 were receiving some type
of b-blocker. The juxtaposition of these results suggests that
the underutilization of b-blockers appears to be present in all
stages of kidney disease including in the chronic dialysis
patients. The four major reasons cited for this low utilization
are as follows: (1) therapeutic nihilism for these chronically
ill patients; (2) the unconventional epidemiology of CVD in
this population; (3) the paucity of efficacy data in patients
with serum creatinine 42.0 mg dl1; and (4) the potential for
higher rates of adverse effects, including hypotension,
hyperkalemia, and glycemic abnormalities.40
Limitations of this study should be noted. First, the
analysis of cardioprotective medication, like b-blockers, in a
retrospective cohort analysis is prone to potential bias, as the
use of b-blockers was not randomized. Despite using
propensity to adjust as much as possible for the bias inherent
in the decision about b-blocker therapy,41 we cannot exclude
the possibility of residual confounding. Second, the analysis
was performed on the basis that if patients were or not
receiving b-blocker therapy on the day of hospital admission,
we could not assess changes in the type or dosage of b-
blockers after the initiation of the study. Third, the study
Table 4 | Multivariate associations of the level of baseline kidney function, b-blocker therapy, and short- and long-term
mortality
Short-term all-cause mortality Long-term all-cause mortality
Unadjusted
Adjusted for
confoundersa
Adjusted for
confounders and
propensity scoreb Unadjusted
Adjusted for
confoundersa
Adjusted for
confounders and
propensity scoreb
OR (95% CI) OR (95% CI) OR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
All patients (n=2126)
b-Blocker therapy 0.48 (0.31–0.74) 0.34 (0.21–0.55) 0.39 (0.24–0.64) 0.91 (0.81–1.03) 0.79 (0.69–0.90) 0.82 (0.71–0.93)
Patients with CrClX60 ml min1 (n=1358)
b-Blocker therapy 0.54 (0.28–1.03) 0.36 (0.17–0.74) 0.39 (0.19–0.83) 1.06 (0.90–1.24) 0.92 (0.77–1.11) 1.01 (0.84–1.22)
Patients with CrClo60 ml min1 (n=768)
b-Blocker therapy 0.45 (0.25–0.79) 0.32 (0.17–0.61) 0.35 (0.19–0.72) 0.74 (0.61–0.88) 0.62 (0.51–0.76) 0.62 (0.50–0.76)
ACE inhibitors, angiotensin-converting enzyme inhibitors; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CrCl, creatinine clearance; HR, hazard ratio;
OR, odds ratio.
aAdjusted for age, gender, hypertension, diabetes mellitus, smoking, hypercholesterolemia, COPD, body mass index, type of surgery, history of myocardial infarction, coronary
revascularization, heart failure, angina, cerebrovascular disease, and year of operation.
bAdjusted for age, gender, hypertension, diabetes mellitus, smoking, hypercholesterolemia, COPD, body mass index, type of surgery, history of myocardial infarction, coronary
revascularization, heart failure, angina, cerebrovascular disease, year of operation, statins, diuretics, ACE inhibitors, calcium antagonists, nitrates, aspirin, and anti-coagulations.
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Figure 1 | Kaplan–Meier estimate of overall survival by level of
kidney function (CrCl) during 5.9873.68 years of follow-up.
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population included in this analysis is almost entirely
Caucasian, making these results not generalizable to other
populations or places. Finally, our definition of kidney
function was based on a CrCl derived from a single serum
creatinine on the day of the procedure, rather than on a
direct measurement of kidney function like iothalamate
clearance. Additionally, the creatinine value we did use could
have been influenced by cardioprotective medications or
clinical status. It is possible that within-person variation in
serum creatinine resulted in misclassification of kidney
function. Furthermore, we did not collect data regarding
the duration or cause of kidney dysfunction or other signs of
kidney disease such as microalbuminuria or overt proteinur-
ia, which is a well-established risk factor for cardiovascular
mortality.42
In this large observational study, the perioperative
administration of b-blockers was associated with clear and
clinically significant reductions in short- and long-term
mortality in patients with moderate and advanced kidney
dysfunction who underwent high-risk elective vascular
surgery. This study also demonstrates an underuse of b-
blocker therapy in patients with kidney dysfunction under-
going major vascular surgery, which is comparable to other
epidemiologic studies. Although the data reported in this
cohort suggest a beneficial association of b-blockers with
survival in a high-risk patient population, large long-term
clinical trials are desperately needed to evaluate the safety and
efficacy of b-blockers in patients with kidney disease not
requiring dialysis.
MATERIALS AND METHODS
Study design and patient selection
Between January 1993 and June 2006, a cohort of 2126 patients
older than 18 years of age underwent open noncardiac vascular
surgery at Erasmus MC, Rotterdam, the Netherlands, and were
entered into a computerized database. All patients had undergone
elective open infrarenal AAA or lower limb arterial revascularization
procedures. Patients scheduled for lower extremity amputations
were excluded. The analysis was made according to whether or not
patients were taking b-blockers on the day of hospital admission,
and does not incorporate changes in medical treatment during the
follow-up period. All patients agreed on participation in the study,
and the study was conducted according to the Declaration of the
Helsinki Principle.
Baseline characteristics
On all patients the information on cardiovascular risk factors was
recorded and included age, gender, hypertension (defined as systolic
blood pressureX140 mm Hg, diastolic blood pressureX90 mm Hg,
or use of anti-hypertensive medication), diabetes mellitus (the
presence of a fasting blood glucose X140 mg dl1 (X7.8 mmol l1)
or requirement for insulin or oral hypoglycemic agents), smoking
status, hypercholesterolemia (total cholesterol of 4200 mg dl1
(45.2 mmol l1)), COPD according to symptoms and pulmonary
function tests (i.e. forced expiratory volume in 1 s o70% of
maximal age and gender predictive value), body mass index, serum
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Figure 2 | Kaplan–Meier estimate of overall survival by level of kidney function (CrCl) and b-blocker therapy during 5.9873.68 years of
follow-up. —b-Blocker use; . . . . . . . . No b-blocker use.
1532 Kidney International (2007) 72, 1527–1534
o r i g i n a l a r t i c l e GMJM Welten et al.: Kidney disease and b-blocker therapy
creatinine, the presence of ischemic heart disease (prior MI, prior
coronary revascularization and angina pectoris), heart failure
(defined according to the New York Heart Association classifica-
tion), cerebrovascular disease (history of cerebrovascular accident or
transient ischemic attack), and preoperative medication use (b-
blockers, statins, diuretics, ACE inhibitors, calcium antagonists,
nitrates, aspirin, and anti-coagulants). All prescription and over-the-
counter medications were noted on the day of admission and were
ascertained if medication was documented at least 1–3 months
before hospital admission for surgery.
Kidney function assessment
Fasting serum creatinine was measured preoperatively in all patients,
either at the outpatient preoperative screening visit or on the day of
hospital admission. Serum creatinine was assessed by a nonkinetic
alkaline picrate (Jaffe) method.43 Because a number of factors such
as age and gender can influence serum creatinine concentra-
tions,44,45 the level of kidney function was defined by CrCl using the
Cockcroft and Gault formula, which includes measures of age,
weight, and sex:
CrCl (ml min1)¼ (140age)*(body weight)/72*serum creati-
nine (multiplied by 0.85 in women),46 where serum creatinine is in
mg dl1, age is in years, and weight is in kilograms.
Classification of kidney function
Patients were divided into four categories, based on the baseline
CrCl value: X90, (reference); 60–89; 30–59, and o30 ml min1.
These cutoffs were chosen on the basis of the National Kidney
Foundation’s (NKF) Kidney Disease Outcomes Quality Initiative
(KDOQI) guidelines as they correspond to the different stages
of CKD.47,48
Clinical follow-up and end points
Postoperative clinical information was retrieved from an electronic
database of patients maintained in our hospital. From the municipal
civil registries, we obtained the survival status. Follow-up was
complete in 97.9%. The primary end point of this analysis was the
composite of short- and long-term all-cause mortality. Short-term
mortality was defined as all deaths occurring during postoperative
in-hospital stay or after hospital discharge but within the first 30
days after surgery. Long-term mortality was defined as death
occurring in the first 10 years after surgery. For both the short- and
long-term mortality survival time was calculated from the date of
surgery to the date of censoring for the occurrence of death.
Data analysis
Continuous data are described as mean values and their standard
deviations (SDs), and dichotomous data are described as percentage
frequencies. The w2-test was used for categorical variables, and the
analysis of variances test was used for continuous variable to
evaluate differences in baseline characteristics between b-blocker
users and between the four kidney function categories.
We developed a propensity score for the likelihood of receiving
b-blocker therapy, and applied a multivariable logistic regression
analysis to calculate the propensity score. The variables included in
the model were age, gender, hypertension, diabetes mellitus,
smoking, hypercholesterolemia, COPD, body mass index, type of
surgery, history of MI and coronary revascularization, heart failure,
angina, cerebrovascular disease, year of operation, and use of statins,
diuretics, ACE inhibitors, calcium antagonists, nitrates, aspirin, and
anti-coagulation.
Kaplan–Meier survival analysis was used to describe the
incidence of death over time. The log-rank test was applied to
study differences in survival between the four categories of kidney
function (X90, 60–89, 30–59, and o30 ml min1) and the
association with b-blocker use within different categories of kidney
function. For further evaluation, the multivariate logistic regression
analysis and the Cox proportional hazard regression analysis, with
adjustment for confounders and propensity, were performed for the
short- and long-term analysis, respectively. All potential confoun-
ders (age, gender, hypertension, diabetes mellitus, smoking,
hypercholesterolemia, COPD, body mass index, type of surgery,
history of MI, coronary revascularization, heart failure, angina,
cerebrovascular disease, and year of operation) were entered in the
multivariable model to ensure an unbiased estimate for the relation
between b-blocker use and short- and long-term all-cause mortality
for all patients and for the different stages of kidney dysfunction.
Unadjusted and adjusted ORs and HRs were reported with
corresponding 95% CIs. Po0.05 was considered to be significant.
All computations were performed with SPSS software version 12.0.1
(SPSS Inc., Chicago, IL, USA), running under Windows 2000
Professional.
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